Neurocrine Biosciences (NBIX)

[TheFinalCD]

good PII (+) data but still needs to go thru FDA

The data from the study will allow Neurocrine to submit a so-called "End of Phase II" meeting request, as well as finalize the initial draft for Phase III, both of which the company expects to file with the Food and Drug Administration in the first half of this year.